Note that there already exist drugs, some of which are FDA approved but not necessarily for any one of the adenocarcinomas, that interact with, e.g., MAPK14, CDKN1A, and RAD51AP1. 41By using this information in clinical practice, therefore, it can be expected to improve the prognostics, diagnostics, and therapeutics of the disease. Here, CDKN1A is linked to adenocarcinoma.